乳癌组织t—PA值检测的临床意义

为探讨组织型纤溶酶原激活物(t—PA)在乳癌组织内的水平状况,我们用底物发色法测定69例乳癌组织和33例乳房纤维瘤组织t—PA值,并结合患者临床分明。淋巴结转移情况、月经状况、雌孕激素受体、多药耐药基因表达状况进行分析.结果表明:t—PA值在乳癌组(n=69)为98±47Iu/mg蛋白,略高于纤维瘤组(87±40,n=33,无统计学差别,激素受体(ER,PR)双阳性组t—PA值(125±37)显著高于其他组,随临床分期Ⅰ→Ⅲ,t—PA值呈显著下降趋势(P<0.01),t—PA值与其他临床病理参数无相关性。t—PA值可以补充说明体内雌孕激素受体功能状态,为激素疗法提供更多信息并提示临床病程。

Measurement of t-PA in Breast Cancer Tissue and its Signifcance

To study the status of tissue-type plasminogen activator (t-PA) in breast cancer tissue and its signifcance. We measured tissue t-PA from 69 patients with breast cancer and 33 patients with fibroma by means of substrate colorimetry method,The relations were also analysed between t-PA and other clinico-pathological data such as clinical stage,lymph node and menstruation status,steriod receptor,MDR1.The results showed that 1. the level of t-PA was 98±47Iu/mg protein in 69 patients with breast cancer and 87±40iu/mg protein in 33 patients with breast fibroma,and were no different in both groups,2. t-PA was significantly increased with ER+PR+of breast cancer(125±37). 3. T-PA was decreasing as the clinical stage being from ⅠtoⅢ(P <0. 01). There is no relation between t-PA and other clinical-pathological factor. We concluded that t - PA level can reflect the functional status of steroid receptor and clinical stage.